Evidence map›Paper›PMID 41358143›Full record

ArticleJCO oncology advances2025

Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Prior anti-PD-1/L1 Exposure (NCI/SWOG S1609).

Megan Othus, Sandip P Patel, Young Kwan Chae, Eliana Dietrich, Manmeet S Ahluwalia, Razelle Kurzrock

Abstract read
In one paragraph

Article in JCO oncology advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Megan OthusSWOG Cancer Research Network Statistical Center, Seattle, WA.
Sandip P PatelUniversity of California at San Diego Moores Cancer Center, La Jolla, CA.
Young Kwan ChaeNorthwestern University, Chicago, IL.
Eliana DietrichFred Hutchinson Cancer Center, Seattle, WA.
Manmeet S AhluwaliaMiami Cancer Institute, Miami, FL.
Razelle KurzrockMedical College of Wisconsin, Milwaukee, WI.

Funding

SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Michael L. LeBlanc · 2014 to 2026
$115.2M
Medical College of Wisconsin Lead Academic Participating Site RenewalUG1CA233198 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI William H Bradley, Elizabeth M Gore · 2019 to 2026
$5.0M
Radiomic spatial maps for identifying viable tumor extent on multi-parametric MRI for GlioblastomaR01CA277728 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Manmeet Ahluwalia, Pallavi Tiwari · 2024 to 2026
$3.0M
Quantitative imaging phenotypic classifier for distinguishing radiation effects from tumor recurrence in Glioblastoma .R01CA264017 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Manmeet Ahluwalia, Pallavi Tiwari · 2022 to 2026
$2.9M
NCI NIH HHS R01 CA264017NCI NIH HHS R01 CA277728NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA233198
6 · The paper itself

Abstract

Background: There are limited data on response and survival outcomes for patients who receive the combination of anti- Methods: Logistic and Cox regression models were used to evaluate associations between prior anti- Results: CBR was not significantly different between those with and without prior anti-PD-1/L1 exposure, 26% in both groups. There were no significant differences in PFS and OS between patients with and without prior anti- Conclusions: There were no statistically or clinically significant differences in outcomes with and without prior anti-

Indexed as

CTLA-4PD-1 failureRare cancers

Identifiers

PMID41358143
PMCPMC12680016

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.